Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05768269 · ClinicalTrials.gov registry record
A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product
A clinical trial of Hematological Malignancy and Solid Tumor Malignancy, sponsored by Century Therapeutics.
- Recruiting
- Registry status
- 375
- Enrollment target
- 7
- Study locations
NCT05768269: Recruiting study of Hematological Malignancy and Solid Tumor Malignancy, sponsored by Century Therapeutics.
NCT05768269 is a study of Hematological Malignancy and Solid Tumor Malignancy that is actively recruiting participants, run by Century Therapeutics. The registered enrollment target is 375 participants, above the 80-participant average among 9 other Hematological Malignancy trials with a reported enrollment target (369% higher). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05768269, a study of Hematological Malignancy and Solid Tumor Malignancy, is actively recruiting participants, sponsored by Century Therapeutics.
- RECRUITING
- Registry status
- 375 participants
- Enrollment target
- 7
- Study locations
Study Summary
This study is designed to collect long-term safety and survival data from participants previously treated in an eligible Century-sponsored index trial. This is an observational study, and the elements of the study design allow for important follow-up for safety, survival, and the continued evaluation of any late adverse events (AEs) that may appear after treatment with such cellular products. Additionally, collection of persistence data from participants will support the identification of any long-term risks or late AEs that may be causally related to treatment with such cellular products.
Conditions Studied
Interventions
- OTHER No Intervention
Study Locations (7)
Arizona
- Banner MD Anderson Cancer Center - Gilbert
California
- University of Southern California - Norris Comprehensive Cancer Center - Los Angeles
Maryland
- University of Maryland Medical Center - Baltimore
Michigan
- Corewell Health - Grand Rapids
North Carolina
- Levine Cancer Institute - Charlotte
Ohio
- University of Cincinnati Medical Center - Cincinnati
Washington
- Swedish Cancer Institute - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 375 participants |
| Start Date | 2024-04-29 |
| Est. Completion | 2040-03 |
What NCT05768269 shows while recruiting
NCT05768269 is an observational study that tracks outcomes without assigning an intervention. The registered 375 participants enrollment target is mid-sized for trials with a published cap, above the 80-participant average among 9 other Hematological Malignancy trials with a reported enrollment target (369% higher).
The record links to 2 conditions, with Hematological Malignancy appearing as the primary indexed condition, and to 1 intervention - of which No Intervention is the first listed.
NCT05768269 lists 7 locations in 7 states (Arizona, California, Maryland).
Frequently Asked Questions
What is clinical trial NCT05768269 about?
NCT05768269 is a clinical study titled "A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product". This study is designed to collect long-term safety and survival data from participants previously treated in an eligible Century-sponsored index trial. This is an observational study, and the elements of the study design allow for important follow-up for safety, survival, and the continued evaluatio...
What is the current status of trial NCT05768269?
This trial is currently recruiting. The enrollment target is 375 participants. The study started on 2024-04-29. Estimated completion is 2040-03.
What conditions does trial NCT05768269 study?
This clinical trial studies the following conditions: Hematological Malignancy, Solid Tumor Malignancy.
What interventions are being tested in trial NCT05768269?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT05768269?
This trial is sponsored by Century Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05768269 being conducted?
This trial has 7 study locations across Arizona, California, Maryland, Michigan, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematological Malignancy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05768269's enrollment target sits among peer trials
375 1st of 9 higher than 9 of 9 other Hematological Malignancy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hematological Malignancy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia
RECRUITING · Phase 2
-
HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib
RECRUITING · Phase 2
-
A Pilot Prospective Clinical Trial Using Remote Monitoring for Cancer Patients Undergoing Outpatient Chemotherapy
RECRUITING
-
Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances
RECRUITING · Phase 1
-
Membrane Target Detection for Leukemia Treatment
RECRUITING
-
Effect of Body Mass on Filgrastim Pharmacokinetics
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03686124 · 375 participants · Phase 1
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- NCT04059172 · 375 participants · Early Phase 1
Efficacy of Combined Ibuprofen and Acetaminophen Therapy Versus Ibuprofen Alone Versus Placebo Alone for Pain Management
- NCT04134923 · 375 participants
Imaging Biomarkers in Preclinical and Symptomatic AD
- NCT04569747 · 375 participants · Phase 2
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI